|
WO2021067863A2
|
|
Targeted il-12 heterodimeric fc-fusion proteins
|
|
WO2021026387A2
|
|
HETERODIMERIC IgG-LIKE BISPECIFIC ANTIBODIES
|
|
WO2020236655A1
|
|
Il-7-fc-fusi0n proteins
|
|
WO2020205516A1
|
|
Dosing of a bispecific antibody that binds pd1 and ctla4
|
|
US2020317814A1
|
|
Heterodimeric antibodies that bind enpp3 and cd3
|
|
WO2020172631A2
|
|
Untargeted and targeted il-10 fc-fusion proteins
|
|
WO2020132646A1
|
|
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
|
US2020140512A1
|
|
Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
|
|
WO2020072821A2
|
|
Il-12 heterodimeric fc-fusion proteins
|
|
TW202011984A
|
|
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
AU2019256529A1
|
|
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
|
|
KR20210003813A
|
|
IL-15/IL-15Rα Fc-fusion protein and LAG-3 targeting heterodimer fusion protein containing the LAG-3 antigen binding domain
|
|
KR20210010862A
|
|
IL-15/IL-15Rα Fc-fusion protein and PD-1 targeting heterodimer fusion protein containing PD-1 antigen binding domain and uses thereof
|
|
CA3096052A1
|
|
Heterodimeric antibodies that bind fibroblast activation protein
|
|
US2020172590A1
|
|
Methods of treating neurological diseases
|
|
KR20200100098A
|
|
Engineered IL-2 FC fusion protein
|
|
EP3706793A1
|
|
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
|
US2019270816A1
|
|
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
US2019270810A1
|
|
Optimized antibody variable regions
|
|
US2019016778A1
|
|
TARGETED HETERODIMERIC Fc FUSION PROTEINS CONTAINING IL-15 IL-15alpha AND ANTIGEN BINDING DOMAINS
|
